VNS

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Retrieved on: 
Wednesday, February 21, 2024

Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed.

Key Points: 
  • Tivic Health® Systems, Inc. (“Tivic”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced today that enrollment in its pilot clinical study of a proprietary approach to non-invasive vagus nerve stimulation (VNS) has been completed.
  • VNS is a growing market that is part of the $8.3B global neurostimulation market, which has a projected CAGR of 12.2%, according to Global Market Insights.
  • Tivic is testing a proprietary approach to more precisely influence vagus nerve signals, while enhancing effectiveness and safety with a non-invasive treatment.
  • “With study enrollment completed less than six months from initiation, we are looking forward to receiving and analyzing the final study results.

Partnership Between VNS Health and Elderwood Health Plan Aims to Bolster Local Managed Long-Term Care in Western New York

Retrieved on: 
Wednesday, February 21, 2024

NEW YORK, Feb. 21, 2024 /PRNewswire/ -- VNS Health, which operates the largest nonprofit managed long-term care plan (MLTC) in New York State, has entered into an agreement with Elderwood Health Plan (Elderwood) to enroll members of Elderwood's MLTC Plan into VNS Health's MLTC, pending New York State Department of Health (NYSE: DOH) approval.

Key Points: 
  • NEW YORK, Feb. 21, 2024 /PRNewswire/ -- VNS Health, which operates the largest nonprofit managed long-term care plan (MLTC) in New York State, has entered into an agreement with Elderwood Health Plan (Elderwood) to enroll members of Elderwood's MLTC Plan into VNS Health's MLTC, pending New York State Department of Health (NYSE: DOH) approval.
  • With approval by NYS DOH, the partnership will allow MLTC members from Elderwood to transfer to VNS Health, or to choose another MLTC plan in the area.
  • "VNS Health and Elderwood are committed to ensuring this transition is a smooth one, with no disruption or change in care for any Elderwood members moving over to VNS Health's MLTC," notes Dan Savitt, President and CEO of VNS Health.
  • VNS Health understands the importance of our Western New York community and keeping a local presence through Elderwood.

Pulsetto Unveils Groundbreaking Vagus Nerve Stimulation Device at CES

Retrieved on: 
Thursday, January 4, 2024

Pulsetto, a leader in Vagus Nerve Stimulation technology, is showcasing at CES its unique dual-technology system and personalized app designed to alleviate stress, reduce anxiety, improve sleep, and manage pain, exemplifying a practical and everyday approach to enhancing mental wellness.

Key Points: 
  • Klaipeda County, Lithuania--(Newsfile Corp. - January 4, 2024) - Pulsetto is set to showcase at CES in Las Vegas, bringing its effective Vagus Nerve Stimulation (VNS) device into the spotlight.
  • A pivotal moment came when he encountered an article about vagus nerve stimulation, sparking the idea for Pulsetto.
  • This device innovatively activates the vagus nerve, a key player in regulating stress responses in the body.
  • On this note, Pulsetto invites all CES attendees to booth 8867 for a hands-on experience with its transformative Vagus Nerve Stimulation device.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Aurora Payments Acquires VN Systems

Retrieved on: 
Wednesday, October 18, 2023

Aurora Payments, LLC announces the acquisition of VN Systems, a Georgia-based Merchant Services Provider specializing in providing merchant services and software for Vietnamese-owned salons.

Key Points: 
  • Aurora Payments, LLC announces the acquisition of VN Systems, a Georgia-based Merchant Services Provider specializing in providing merchant services and software for Vietnamese-owned salons.
  • VN Systems has been highly focused on delivering solutions to the salon industry for years, particularly the nail salon industry.
  • The partnership of Aurora Payments, NailSoft, and VN Systems is another example of Aurora’s commitment to the salon industry.” VN Systems and NailSoft are both based in Atlanta.
  • 733Park , a boutique Boston-based M&A firm specializing in payments and SAAS, advised VN Systems on the transaction.

Pathway to Cures Announces Venture Investment in Five Liters

Retrieved on: 
Monday, October 16, 2023

Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.

Key Points: 
  • Pathway to Cures (P2C) announced today its investment of $500,000 in Five Liters, a subsidiary of Spark Biomedical, to develop therapies for treating inheritable blood and bleeding disorders.
  • Pathway to Cures, an affiliate of the National Bleeding Disorders Foundation, is a venture philanthropy fund focused on early-stage companies developing cures, therapies, or enabling technologies in support of the inheritable blood and bleeding disorders community.
  • This significant milestone is made possible through Five Liters' collaboration with Northwell Health’s Feinstein Institutes for Medical Research in New York.
  • Dr. Recht is Chief Medical and Scientific Officer at both Pathway to Cures and the National Bleeding Disorders Foundation (NBDF) and chairs the Pathway to Cures Scientific Advisory Group.

Federman & Sherwood Investigates VNS Health Plans for Data Breach

Retrieved on: 
Wednesday, August 16, 2023

The law firm of Federman & Sherwood has initiated an investigation into VNS Health Plans with respect to their recent data breach.

Key Points: 
  • The law firm of Federman & Sherwood has initiated an investigation into VNS Health Plans with respect to their recent data breach.
  • On August 14, 2023 through August 21, 2023, VNS Health Plans notified individuals that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company.
  • According to VNS Health Plans, they determined that information moved through file transfer tool, MOVEit Transfer may have been subject to unauthorized access between May 30, 2023 and June 2, 2023.
  • VNS Health Plans determined that the information exposed in the data breach includes: name, mailing address, telephone number, email address, date of birth, social security number, member ID, Medicare and/or Medicaid number, benefit and subsidy information, billing information, medical claims information, healthcare provider name and specialty, and dates of service.

gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

Retrieved on: 
Tuesday, July 25, 2023

PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.

Key Points: 
  • PTSD is an extreme mental health condition associated with changes in multiple neurophysiological systems such as inflammation and the autonomic nervous system and contributing to deficits in memory.
  • Many patients have limited or no response to currently available treatments for PTSD symptoms and associated cognitive dysfunction.
  • Vagus Nerve Stimulation (VNS) has been shown in preliminary studies to enhance function when paired with cognitive and motor tasks.
  • The study concluded the active group developed better attention and recall of paragraphs encoded with stimulation as well as for working memory tasks as compared to sham.

Evren Technologies Announces Launch of Revolutionary Phoenix®100 System for Vagus Nerve Stimulation Research

Retrieved on: 
Thursday, July 13, 2023

GAINESVILLE, Fla., July 13, 2023 /PRNewswire/ -- Evren Technologies, an innovator in the field of medical neuromodulation devices, today announced the launch of its pioneering Phoenix® 100 System, a state-of-the-art transcutaneous auricular vagus nerve stimulator (taVNS) research tool.

Key Points: 
  • GAINESVILLE, Fla., July 13, 2023 /PRNewswire/ -- Evren Technologies, an innovator in the field of medical neuromodulation devices, today announced the launch of its pioneering Phoenix® 100 System, a state-of-the-art transcutaneous auricular vagus nerve stimulator (taVNS) research tool.
  • Evren Technologies announced the launch of its pioneering Phoenix® CR-100 System, a state-of-the-art research tool.
  • The Phoenix 100 System solves long-standing challenges faced by researchers in the realm of Vagus Nerve Stimulation (VNS).
  • The Phoenix 100 stimulates the vagus nerve via the ear's pinna, downregulating the sympathetic nervous system to reduce stress response.

Five Liters sets clinical sights on novel bioelectric treatment for von Willebrand Disease

Retrieved on: 
Thursday, July 6, 2023

Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).

Key Points: 
  • Five Liters, a subsidiary of Spark Biomedical, is dedicated to exploring the hemostatic effects of vagus nerve stimulation (VNS), specifically transcutaneous auricular neurostimulation (tAN).
  • Dr. Navid Khodaparast, Chief Science Officer of Spark and Five Liters stated “Von Willebrand Disease is an inherited bleeding disorder in which blood does not clot properly, leading to bleeding events and joint problems.
  • At Five Liters, our primary clinical initiative is to demonstrate that tAN therapy can safely alleviate menorrhagia in females with VWD.
  • Thanks to this partnership and the Nature article, Five Liters is thrilled to move forward with its mission.